What an Overturned Denial Is Actually Measuring
Prior authorization transparency created public visibility into what health plans are deciding. Overturn rates are part of that picture, and as CMS enforcement expands, they are becoming one of the more closely watched numbers in the dataset. But an overturned denial is not a single operational event. It is a category that contains several different ones, and the distinction between them mostly disappears once the outcome enters reporting.
The Outcome Is Not the Story
When a prior authorization denial gets overturned, public reporting records one thing: the denial was reversed. That outcome enters the dataset, gets aggregated with every other overturn, and eventually surfaces as a rate.
What it does not preserve is how the reversal happened, or why.
An overturned denial can mean that additional clinical documentation was submitted after the initial decision. It can mean that a second reviewer interpreted the same clinical picture differently than the first. It can mean that new information surfaced during the appeal that changed the evidentiary basis of the case. From the outside, those situations are indistinguishable. The metric collapses them into a single category and moves on.
What Maximus Introduces Into the Equation
For Medicare Advantage appeals, cases that are not resolved internally can eventually reach the Part C Independent Review Entity for external review. C2C Innovative Solutions became the Part C Independent Review Entity on May 1, 2026, replacing Maximus for newly received cases. Once a case moves outside the plan’s own review structure, it is no longer being evaluated internally. An external reviewer is examining how the denial was constructed, whether the documentation supports it, and whether it holds up against the applicable coverage criteria.
An overturn at that stage occurs under different conditions than one that happened earlier in the process, and it carries different implications for Star Ratings and CMS audit exposure. Once a case reaches external review, the final decision no longer rests with the health plan.
That distinction surfaced in a conversation about how appeal resolution actually works: “We don’t want this to go to Maximus.” The comment highlights a distinction the overturn rate does not preserve. A denial reversed internally and a denial reversed at external review both enter the same reporting category. The pathway that produced each outcome does not.
What the Data Can and Cannot Tell You
The overturn rate at any single point in time has limited analytical value on its own. The more useful question is whether it has changed, and what was happening at the same time it did. A significant shift in appeal overturn rates, upheld appeals, or total appeal volume is worth examining even without knowing the cause — because the public data can identify that a shift occurred, but determining what produced it often requires information that exists outside the reporting itself.
Overturn rates describe the frequency of reversals. The circumstances that produced those reversals largely do not travel with the metric. As prior authorization reporting becomes more widely used, that distinction may become increasingly important. The data can identify that a denial was overturned. Understanding why it was overturned is often a separate question.
The Prior Auth Report identifies the prior authorization developments that actually matter each month and explains what they mean operationally, for the people making decisions and the people doing the work.
If you want that analysis delivered directly to your inbox each month, the newsletter signup is below.